{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:58:32Z","timestamp":1790009912819,"version":"4.0.1"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:p>\n                    The objective of this study is to present the characteristics of cerebral type adrenoleukodystrophy (cALD) and our hematopoietic stem cell transplantation (HSCT) experience in treating cALD. A retrospective analysis and summary of the clinical data pertaining to 10 patients after allogeneic HSCT (allo-HSCT) was conducted from June 2020 to October 2023. Six patients exhibited no neurological symptoms, and MRI of 5 cases revealed no abnormalities at the onset of the disease. The 3-year overall survival (OS) and event-free survival (EFS) rate was 90.0% (95% CI: 69.4-100.0) and 65.6% (95% CI: 35.6-98.4), respectively. Survival analysis showed unrelated donor choice was associated with a superior OS and EFS compared with related donor sources, but these differences were not statistically significant (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.414, 0.184). cALD patients without magnetic resonance imaging (MRI) abnormalities at the initial onset of the disease increased the OS compared with the patients with MRI abnormalities, and the OS of patients with NFS=0 was superior before HSCT to those with NFS \u22651, however, the differences were not significant. But the EFS was obviously superior to those cALD patients with abnormal MRI status (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.013) at the initial onset of the disease and neurological functional symptoms before HSCT (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.023). Early screening is necessary for children with a family history of suspected genetic diseases and atypical neurological symptoms to improve allo-HSCT outcomes.\n                  <\/jats:p>","DOI":"10.1097\/mph.0000000000003069","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T12:00:25Z","timestamp":1753358425000},"page":"284-290","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Cerebral Adrenoleukodystrophy: Characteristics of 10 Cases Including 6 Patients Without Neurologic Symptoms"],"prefix":"10.1097","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8618-2671","authenticated-orcid":false,"given":"Yafeng","family":"Wang","sequence":"first","affiliation":[{"name":"Hematology and Oncology"},{"name":"Henan Provincial Key Laboratory of Children\u2019s Genetics and Metabolic Diseases, Children\u2019s Hospital Affiliated to Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Liu","sequence":"additional","affiliation":[{"name":"Electrocardiogram, Children\u2019s Hospital Affiliated to Zhengzhou University, Henan Children\u2019s Hospital, Zhengzhou Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haili","family":"Gao","sequence":"additional","affiliation":[{"name":"Hematology and Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[{"name":"Hematology and Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1953-4195","authenticated-orcid":false,"given":"Yanna","family":"Mao","sequence":"additional","affiliation":[{"name":"Hematology and Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"key":"R1-20260422","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1210\/endrev\/bnaa013","article-title":"The changing face of adrenoleukodystrophy","volume":"41","author":"Zhu","year":"2020","journal-title":"Endocr Rev"},{"key":"R2-20260422","doi-asserted-by":"crossref","first-page":"895511","DOI":"10.3389\/fncel.2022.895511","article-title":"Hematopoietic stem cell transplantation for neurological disorders: a focus on inborn errors of metabolism","volume":"16","author":"de Vasconcelos","year":"2022","journal-title":"Front Cell Neurosci"},{"key":"R3-20260422","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1212\/WNL.0000000000201374","article-title":"International recommendations for the diagnosis and management of patients with adrenoleukodystrophy: a consensus-based approach","volume":"99","author":"Engelen","year":"2022","journal-title":"Neurology"},{"key":"R4-20260422","first-page":"1761","article-title":"Adrenoleukodystrophy: a scoring method for brain MR observations","volume":"15","author":"Loes","year":"1994","journal-title":"AJNR Am J Neuroradiol"},{"key":"R5-20260422","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/978-1-4419-9072-3_47","article-title":"Evaluation of the preventive effect of glyceryl trioleate-trierucate (\u201cLorenzo\u2019s oil\u201d) therapy in X-linked adrenoleukodystrophy: results of two concurrent trials","volume":"544","author":"Moser","year":"2003","journal-title":"Adv Exp Med Biol"},{"key":"R6-20260422","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/14737175.2020.1699060","article-title":"An update on clinical, pathological, diagnostic, and therapeutic perspectives of childhood leukodystrophies","volume":"20","author":"Ashrafi","year":"2020","journal-title":"Expert Rev Neurother"},{"key":"R7-20260422","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1182\/bloodadvances.2021005294","article-title":"Variables affecting outcomes after allogeneic hematopoietic stem cell transplant for cerebral adrenoleukodystrophy","volume":"6","author":"Chiesa","year":"2022","journal-title":"Blood Adv"},{"key":"R8-20260422","doi-asserted-by":"crossref","first-page":"e591","DOI":"10.1212\/WNL.0000000000009929","article-title":"Neurocognitive benchmarks following transplant for emerging cerebral adrenoleukodystrophy","volume":"95","author":"Pierpont","year":"2020","journal-title":"Neurology"},{"key":"R9-20260422","doi-asserted-by":"crossref","first-page":"e363","DOI":"10.1016\/j.bbmt.2019.09.003","article-title":"Hematopoietic stem cell transplantation to treat leukodystrophies: clinical practice guidelines from the Hunter\u2019s Hope Leukodystrophy Care Network","volume":"25","author":"Page","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"R10-20260422","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1093\/brain\/awy127","article-title":"Impaired plasticity of macrophages in X-linked adrenoleukodystrophy","volume":"141","author":"Weinhofer","year":"2018","journal-title":"Brain"},{"key":"R11-20260422","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1182\/blood-2018-11-887240","article-title":"Successful donor engraftment and repair of the blood-brain barrier in cerebral adrenoleukodystrophy","volume":"133","author":"Orchard","year":"2019","journal-title":"Blood"},{"key":"R12-20260422","doi-asserted-by":"crossref","first-page":"15018","DOI":"10.1073\/pnas.1205858109","article-title":"Brain conditioning is instrumental for successful microglia reconstitution following hematopoietic stem cell transplantation","volume":"109","author":"Capotondo","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R13-20260422","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.bbmt.2018.09.036","article-title":"Survival and functional outcomes in boys with cerebral adrenoleukodystrophy with and without hematopoietic stem cell transplantation","volume":"25","author":"Raymond","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"R14-20260422","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.pediatrneurol.2007.06.011","article-title":"Immune response in leukodystrophies","volume":"37","author":"Eichler","year":"2007","journal-title":"Pediatr Neurol"},{"key":"R15-20260422","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/bloodadvances.2017010645","article-title":"Early and late outcomes after cord blood transplantation for pediatric patients with inherited leukodystrophies","volume":"2","author":"van den Broek","year":"2018","journal-title":"Blood Adv"},{"key":"R16-20260422","doi-asserted-by":"crossref","first-page":"e180769","DOI":"10.1001\/jamanetworkopen.2018.0769","article-title":"Potential risks to stable long-term outcome of allogeneic hematopoietic stem cell transplantation for children with cerebral X-linked adrenoleukodystrophy","volume":"1","author":"Kuhl","year":"2018","journal-title":"JAMA Netw Open"},{"key":"R17-20260422","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1590\/0004-282x20160155","article-title":"Neurological outcomes after hematopoietic stem cell transplantation for cerebral X-linked adrenoleukodystrophy, late onset metachromatic leukodystrophy and Hurler syndrome","volume":"74","author":"Saute","year":"2016","journal-title":"Arq Neuropsiquiatr"},{"key":"R18-20260422","doi-asserted-by":"crossref","first-page":"999919","DOI":"10.3389\/fneur.2022.999919","article-title":"Unrelated umbilical cord blood transplantation for children with hereditary leukodystrophy: a retrospective study","volume":"13","author":"Wang","year":"2022","journal-title":"Front Neurol"},{"key":"R19-20260422","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3390\/ijns8020029","article-title":"Newborn screening for X-linked adrenoleukodystrophy in nebraska: initial experiences and challenges","volume":"8","author":"Baker","year":"2022","journal-title":"Int J Neonatal Screen"},{"key":"R20-20260422","doi-asserted-by":"crossref","first-page":"4025073","DOI":"10.1155\/2016\/4025073","article-title":"Donor specific anti-HLA antibody and risk of graft failure in haploidentical stem cell transplantation","volume":"2016","author":"Kongtim","year":"2016","journal-title":"Adv Hematol"},{"key":"R21-20260422","doi-asserted-by":"crossref","first-page":"e14735","DOI":"10.1111\/petr.14735","article-title":"Haploidentical hematopoietic stem cell transplantation with busulfan, cyclophosphamide, and fludarabine conditioning for X-linked adrenal cerebral leukodystrophy","volume":"28","author":"Chen","year":"2024","journal-title":"Pediatr Transplant"},{"key":"R22-20260422","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41409-017-0015-2","article-title":"Haploidentical bone marrow transplantation with post transplant cyclophosphamide for patients with X-linked adrenoleukodystrophy: a suitable choice in an urgent situation","volume":"53","author":"Fernandes","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"R23-20260422","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/ncpneuro0729","article-title":"Hematopoietic stem cell transplantation for the treatment of childhood cerebral X-linked adrenoleukodystrophy","volume":"4","author":"Maccotta","year":"2008","journal-title":"Nat Clin Pract Neurol"},{"key":"R24-20260422","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1080\/14712598.2022.2124857","article-title":"Treatment of cerebral adrenoleukodystrophy: allogeneic transplantation and lentiviral gene therapy","volume":"22","author":"Gupta","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"R25-20260422","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.3174\/ajnr.A4773","article-title":"Childhood cerebral adrenoleukodystrophy: MR perfusion measurements and their use in predicting clinical outcome after hematopoietic stem cell transplantation","volume":"37","author":"McKinney","year":"2016","journal-title":"AJNR Am J Neuroradiol"},{"key":"R26-20260422","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/ijns8010016","article-title":"Newborn screening for X-linked adrenoleukodystrophy: past, present, and future","volume":"8","author":"Moser","year":"2022","journal-title":"Int J Neonatal Screen"},{"key":"R27-20260422","doi-asserted-by":"crossref","first-page":"107734","DOI":"10.1016\/j.ymgme.2023.107734","article-title":"Newborn screening for adrenoleukodystrophy: international experiences and challenges","volume":"140","author":"Videb\u00e6k","year":"2023","journal-title":"Mol Genet Metab"},{"key":"R28-20260422","doi-asserted-by":"crossref","first-page":"e14015","DOI":"10.1111\/petr.14015","article-title":"Allogeneic hematopoietic stem cell transplantation in patients with childhood cerebral adrenoleukodystrophy: a single-center experience \u201cBetter prognosis in earlier stage\u201d","volume":"25","author":"Yalcin","year":"2021","journal-title":"Pediatr Transplant"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000003069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T08:01:10Z","timestamp":1776844870000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000003069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000003069","relation":{},"ISSN":["1077-4114","1536-3678"],"issn-type":[{"value":"1077-4114","type":"print"},{"value":"1536-3678","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]},"assertion":[{"value":"2024-11-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}